ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Iowa » Pulmonary Disease

Top Pulmonary Disease Prescribers in Iowa

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
RONALD SCHOPE M.D.

Pulmonary Disease

7,762

$368K

352
296 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 54%

$47
Average prescription price

Avg: $170

JAMES BODDICKER MD

Pulmonary Disease

5,064

$434K

532
452 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 54%

$86
Average prescription price

Avg: $170

PAUL MANNING M.D.

Pulmonary Disease

4,342

$327K

280
223 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

40%
prescriptions for brand name drugs

Avg: 54%

$75
Average prescription price

Avg: $170

JAMES MEYER DO

Pulmonary Disease

3,974

$1.05M

472
388 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

59%
prescriptions for brand name drugs

Avg: 54%

$263
Average prescription price

Avg: $170

ELIZABETH DAY DO

Pulmonary Disease

3,435

$635K

351
273 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

54%
prescriptions for brand name drugs

Avg: 54%

$185
Average prescription price

Avg: $170

ANDREW ASHBY MD

Pulmonary Disease

3,298

$441K

353
317 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

61%
prescriptions for brand name drugs

Avg: 54%

$134
Average prescription price

Avg: $170

DONALD PAYNTER MD

Pulmonary Disease

3,227

$434K

372
301 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

45%
prescriptions for brand name drugs

Avg: 54%

$134
Average prescription price

Avg: $170

CHARLES BRUYNTJENS MD

Pulmonary Disease

3,207

$486K

327
231 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

52%
prescriptions for brand name drugs

Avg: 54%

$151
Average prescription price

Avg: $170

UDAYA SHREESHA

Pulmonary Disease

2,883

$484K

323
232 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

69%
prescriptions for brand name drugs

Avg: 54%

$168
Average prescription price

Avg: $170

MARK JANES M.D.

Pulmonary Disease

2,816

$473K

366
314 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

69%
prescriptions for brand name drugs

Avg: 54%

$168
Average prescription price

Avg: $170

GREGORY HICKLIN M.D.

Pulmonary Disease

2,492

$362K

417
344 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

53%
prescriptions for brand name drugs

Avg: 54%

$145
Average prescription price

Avg: $170

STEVEN WANZEK M.D.

Pulmonary Disease

2,233

$831K

369
321 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

75%
prescriptions for brand name drugs

Avg: 54%

$372
Average prescription price

Avg: $170

ALAN MOY MD

Pulmonary Disease

1,937

$286K

323
285 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

68%
prescriptions for brand name drugs

Avg: 54%

$148
Average prescription price

Avg: $170

JULIA KLESNEY TAIT MD, PHD

Pulmonary Disease

1,904

$386K

47
11 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 54%

$203
Average prescription price

Avg: $170

AKSHAY MAHADEVIA MD

Pulmonary Disease

1,885

$201K

262
170 are 65+

7%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

39%
prescriptions for brand name drugs

Avg: 54%

$107
Average prescription price

Avg: $170

JAMES CAFARO MD

Pulmonary Disease

1,589

$170K

203
169 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

48%
prescriptions for brand name drugs

Avg: 54%

$107
Average prescription price

Avg: $170

NEIL HORNING MD

Pulmonary Disease

1,558

$453K

228
167 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

65%
prescriptions for brand name drugs

Avg: 54%

$291
Average prescription price

Avg: $170

AMERLON ENRIQUEZ M.D.

Pulmonary Disease

1,545

$274K

240
177 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

76%
prescriptions for brand name drugs

Avg: 54%

$177
Average prescription price

Avg: $170

VALERIE VELHO MD

Pulmonary Disease

1,537

$258K

252
215 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

62%
prescriptions for brand name drugs

Avg: 54%

$168
Average prescription price

Avg: $170

ANGELA COLLINS M.D.

Pulmonary Disease

1,454

$266K

234
188 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

70%
prescriptions for brand name drugs

Avg: 54%

$183
Average prescription price

Avg: $170

ARVIND PERATHUR MD

Pulmonary Disease

1,436

$252K

254
208 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

52%
prescriptions for brand name drugs

Avg: 54%

$176
Average prescription price

Avg: $170

JORGE ALVAREZ M.D.

Pulmonary Disease

1,392

$591K

226
174 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

65%
prescriptions for brand name drugs

Avg: 54%

$424
Average prescription price

Avg: $170

RAMON REYES M.D.

Pulmonary Disease

1,259

$163K

356
281 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 54%

$130
Average prescription price

Avg: $170

KATRINA GUEST M.D.

Pulmonary Disease

1,255

$140K

213
169 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

46%
prescriptions for brand name drugs

Avg: 54%

$112
Average prescription price

Avg: $170

DAVID VISOKEY DO

Pulmonary Disease

1,235

$201K

176
119 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

72%
prescriptions for brand name drugs

Avg: 54%

$163
Average prescription price

Avg: $170

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank